A Proof-of-concept Study to Evaluate the Benefit From add-on Therapy With Montelukast Versus Salmeterol in Children With Asthma Carrying the Arg/Arg-16 beta2-receptor Genotype.

Trial Profile

A Proof-of-concept Study to Evaluate the Benefit From add-on Therapy With Montelukast Versus Salmeterol in Children With Asthma Carrying the Arg/Arg-16 beta2-receptor Genotype.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2013

At a glance

  • Drugs Montelukast (Primary) ; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 23 Feb 2009 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
    • 01 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top